Tetracycline
As of the edition of 20 October 2026, Tetracycline is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Achromycin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 20 in 5 regions
- Holder of the most recent approval
- Medius AG; 12 holders in all
- Registered trials
- 50, 5 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Infections; Eye; Lungs and airways; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 9 | 1 | 2 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 4 | 4 | 0 | 0 |
| Phase 3 | 4 | 1 | 0 | 0 |
| Phase 4 | 25 | 8 | 4 | 2 |
| All trials | 50 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Acquired holder | 2003 to now |
| Storz Ophthalmics Inc Sub American Cyanamid | Acquired holder | 2003 to now |
| Takeda | Acquired holder | 2005 to now |
| Schiff | Acquired holder | 2011 to now |
| Avet Pharmaceuticals | Acquired holder | 2019 to now |
| Pfizer | Later holder | |
| Procter And Gamble | Later holder |